Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a broader
The recent $571.5 million licensing agreement between SK Biopharmaceuticals Co., Ltd., and Full-Life Technologies Limited marks a significant milestone in the biotech industry. This exclusive deal grants SK Biopharmaceuticals the rights to develop, manufacture, and commercialize FL-091, an
The global obesity epidemic has led to an urgent demand for innovative and effective treatments. Traditional methods like diet, exercise, and surgical interventions present various challenges, often marked by inconsistent results and reduced patient compliance. In response, the pharmaceutical
Cardurion Pharmaceuticals has recently made headlines by securing a $260 million Series B financing round. This substantial investment underscores the fierce commitment to advancing the treatment of heart disease, one of the leading causes of mortality worldwide. The funds raised will propel
Legend Biotech, widely recognized for its collaboration with Johnson & Johnson (J&J) on the BCMA CAR-T therapy Carvykti, has found itself at the center of buyout speculation, which has reverberated across biotech markets. Reports of an acquisition bid prompted the company to engage Centerview
In a groundbreaking partnership aimed at revolutionary advancements in biopharmaceutical research, Pfizer and Evotec have joined forces to discover new therapeutics targeting metabolic and infectious diseases. Announced on July 10, 2024, this collaboration will leverage Evotec’s state-of-the-art
